Dr. Sise’s complete bibliography is available here.
- Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
- Therapeutic advances in COVID-19
- Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
- Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
- Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma
- Immune checkpoint inhibitors and kidney disease
- Onconephrology: The Growth of Cancer-Kidney Connection, Part 2
- Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
- Acute kidney injury caused by haplostorm after allogenic hematopoietic stem cell transplant
- Hispanic ethnicity and mortality among critically ill patients with COVID-19
- Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease
- A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease
- Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment
- Chronic Kidney Disease in Cancer Survivors
- Onconephrology: The Growth of Cancer-Kidney Connection
- One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial
- The association between olfactory and gustatory dysfunction and chronic kidney disease
- Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
- Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD: A Retrospective Cohort Study
- Association of Surge Conditions with Mortality Among Critically Ill Patients with COVID-19
